Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
Clinical trial NCT05039658 · UNKNOWN
Trial details
- NCT number
- NCT05039658
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-27
- Primary completion
- 2022-07-12
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.